#1 Clinical Trials Search in Europe

Netupitant

Netupitant is an innovative drug being studied in clinical trials for its effectiveness in preventing chemotherapy-induced nausea and vomiting (CINV). This article explores how netupitant, often combined with other antiemetic medications, is being tested to improve the quality of life for cancer patients undergoing chemotherapy. The trials focus on different patient populations, dosages, and combinations to determine the optimal use of netupitant in managing CINV.

Table of Contents

What is NETUPITANT?

NETUPITANT is an antiemetic medication, which means it helps prevent nausea and vomiting. It belongs to a class of drugs called NK1 receptor antagonists. NETUPITANT is often used in combination with other medications to provide more comprehensive protection against nausea and vomiting, especially in cancer patients undergoing chemotherapy[1][2].

Other names for NETUPITANT include:

  • CID6451149
  • D05152
  • RO 67-3189/000

These alternative names may be used in scientific literature or by healthcare professionals[3].

How Does NETUPITANT Work?

NETUPITANT works by blocking a specific receptor in the body called the NK1 receptor. This receptor plays a crucial role in triggering nausea and vomiting, especially after chemotherapy. By blocking this receptor, NETUPITANT helps prevent these unpleasant side effects[1].

What Conditions Does NETUPITANT Treat?

The primary condition that NETUPITANT is used to treat is Chemotherapy-Induced Nausea and Vomiting (CINV). This is a common and distressing side effect experienced by cancer patients undergoing chemotherapy treatment. CINV can significantly impact a patient’s quality of life and may even lead to some patients discontinuing their cancer treatment[2][4].

NETUPITANT Combination Therapy

NETUPITANT is often used in combination with other medications to provide more comprehensive protection against CINV. The most common combination is with palonosetron, another anti-nausea medication. This combination is known as NEPA (NEtupitant and PAlonosetron)[1][2].

NEPA is available under the brand name Akynzeo®. It combines 300 mg of netupitant with 0.5 mg of palonosetron in a single oral capsule[4].

In some studies, NEPA is also used in combination with dexamethasone, a steroid that can further enhance the anti-nausea effect[2].

Dosage and Administration

NETUPITANT is typically administered orally (by mouth) before chemotherapy treatment. The standard dose is 300 mg of netupitant, usually combined with 0.5 mg of palonosetron. This is often given as a single dose about an hour before the start of chemotherapy[2].

In some cases, an intravenous (IV) form of the medication may be used. This is called fosnetupitant, which is a prodrug that converts to netupitant in the body. The IV form is typically given as a 30-minute infusion before chemotherapy[5].

Efficacy of NETUPITANT

Clinical trials have shown that NETUPITANT, especially when combined with palonosetron (NEPA), is effective in preventing CINV. The efficacy is often measured by the “complete response” rate, which means no vomiting and no need for rescue medication[2][4].

Studies have looked at the effectiveness of NEPA in both the acute phase (within 24 hours of chemotherapy) and the delayed phase (24-120 hours after chemotherapy). Results have shown good control of nausea and vomiting in both phases[2].

Safety Profile

NETUPITANT is generally well-tolerated by most patients. However, like all medications, it can cause side effects. The safety profile is typically assessed by monitoring for adverse events during clinical trials[5].

Common side effects may include headache, constipation, and fatigue. However, the exact nature and frequency of side effects can vary between individuals. It’s important to discuss potential side effects with your healthcare provider[5].

Use in Special Populations

Research is ongoing to understand how NETUPITANT works in different patient populations. For example, one study is looking at its use in pediatric cancer patients, with dosages adjusted based on the child’s weight[1].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of NETUPITANT. These studies are looking at various aspects, including:

  • Its use in different types of chemotherapy regimens[2]
  • Comparing oral and intravenous forms of the medication[5]
  • Its effectiveness over multiple cycles of chemotherapy[4]
  • Its use in combination with other anti-nausea medications[6]

These ongoing studies aim to provide more information about the best ways to use NETUPITANT to help patients manage CINV and improve their quality of life during cancer treatment.

Aspect Details
Drug Combinations Netupitant + Palonosetron (NEPA), sometimes with Dexamethasone
Patient Populations Adults and children with various cancer types (breast, lung, endometrial)
Administration Methods Oral capsules, intravenous infusion (fosnetupitant)
Primary Outcomes Complete response rates, safety profiles
Secondary Outcomes Nausea control, quality of life impact, pharmacokinetics
Chemotherapy Types Highly emetogenic (HEC) and moderately emetogenic (MEC)
Study Designs Randomized, double-blind, active-controlled, multi-cycle
Assessment Tools FLIE questionnaire, VAS scales, CTCAE criteria

FAQ

  • What is netupitant and how does it work? Netupitant is an antiemetic drug that helps prevent nausea and vomiting. It works by blocking a specific receptor in the body called NK1, which is involved in triggering nausea and vomiting, especially after chemotherapy.
  • How is netupitant typically administered in clinical trials? In most trials, netupitant is given orally, often in combination with another antiemetic drug called palonosetron. It's usually administered as a single dose before chemotherapy, sometimes along with dexamethasone.
  • What types of cancer patients are being studied in netupitant trials? The trials include patients with various types of cancer, including breast cancer, lung cancer, and endometrial cancer. Some studies focus specifically on pediatric cancer patients.
  • What are the main outcomes being measured in these trials? The primary outcomes often include 'complete response' rates, which means no vomiting and no use of rescue medication. Other outcomes include the control of nausea, impact on quality of life, and safety assessments.
  • Are there any new formulations of netupitant being tested? Yes, some trials are testing an intravenous form of netupitant called fosnetupitant. This is being compared to the oral form to see if it offers any advantages in preventing CINV.

Ongoing Clinical Trials on Netupitant

  • Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium France Italy Poland Spain

  • Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • A Study to Evaluate LY3537021 and a Drug Combination for Treating Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Romania Spain

  • Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +7

Glossary

  • CINV: Chemotherapy-Induced Nausea and Vomiting. This refers to the side effects of nausea and vomiting that often occur after receiving chemotherapy treatment.
  • Antiemetic: A type of medication used to prevent or reduce nausea and vomiting.
  • NK1 receptor: Neurokinin-1 receptor, a target for certain antiemetic drugs like netupitant. Blocking this receptor can help prevent nausea and vomiting.
  • Palonosetron: Another antiemetic drug often used in combination with netupitant to prevent CINV.
  • Dexamethasone: A corticosteroid medication often used alongside other antiemetics to help prevent CINV.
  • Complete Response: In CINV studies, this typically means no vomiting and no use of rescue medication during a specified time period.
  • Acute Phase: The first 24 hours after chemotherapy administration, when CINV can occur.
  • Delayed Phase: The period from 24 to 120 hours after chemotherapy, when delayed CINV can occur.
  • HEC: Highly Emetogenic Chemotherapy. Chemotherapy regimens that have a high risk of causing nausea and vomiting.
  • MEC: Moderately Emetogenic Chemotherapy. Chemotherapy regimens that have a moderate risk of causing nausea and vomiting.
  • NEPA: A fixed-dose combination of netupitant and palonosetron used in some clinical trials.
  • Fosnetupitant: An intravenous form of netupitant being tested in some clinical trials.
  • FLIE: Functional Living Index-Emesis, a questionnaire used to assess the impact of CINV on a patient's quality of life.
  • VAS: Visual Analogue Scale, a measurement tool used to assess the severity of nausea or patient satisfaction with treatment.
  • CTCAE: Common Terminology Criteria for Adverse Events, a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy.

References

  1. https://clinicaltrials.gov/study/NCT03204279
  2. https://clinicaltrials.gov/study/NCT03862144
  3. https://clinicaltrials.gov/study/NCT03097588
  4. https://clinicaltrials.gov/study/NCT03649230
  5. https://clinicaltrials.gov/study/NCT03403712
  6. https://clinicaltrials.gov/study/NCT04669132